AI Stock Analysis - Jazz Pharmaceuticals (JAZZ)
Analysis generated November 26, 2025.
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines. With a focus on neuroscience, oncology, and sleep medicine, Jazz has established itself as a key player in the industry. The company operates with a mission to improve patients' lives, bringing innovative therapies to those who need them most.
Stock Alerts - Jazz Pharmaceuticals (JAZZ)
 |
Jazz Pharmaceuticals | March 10 Insider Alert: Carr Patricia is continuing selling shares |
|
Jazz Pharmaceuticals | March 5 Insider Alert: COZADD BRUCE C is selling shares |
|
Jazz Pharmaceuticals | March 3 Insider Alert: Carr Patricia is selling shares |
|
Jazz Pharmaceuticals | February 25 Price is up by 8.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Jazz Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 122 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 68,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,163 | Sign up | Sign up | Sign up |
| X Followers | 3,668 | Sign up | Sign up | Sign up |
| X Mentions | 21 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 40 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,628 | Sign up | Sign up | Sign up |
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
| Price | $180.32 |
| Target Price | Sign up |
| Volume | 715,496 |
| Market Cap | $11.4B |
| Year Range | $105.93 - $196.83 |
| Dividend Yield | 0% |
| PE Ratio | 15.38 |
| Analyst Rating | 88% buy |
| Industry | Biotechnology |
In the news
Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $250February 24 - Benzinga |
|
Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results. Also, B of A Securities maintained a Buy rating on the stock and raised its price target from $263 to $275.February 24 - Benzinga |
|
 |
Analyst Expectations For Jazz Pharmaceuticals's FutureFebruary 24 - Benzinga |
B of A Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $275February 24 - Benzinga |
|
 |
Jazz Pharmaceuticals Q4 Earnings Call HighlightsFebruary 24 - Yahoo |
|
Jazz Pharmaceuticals PLC (JAZZ) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...February 24 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.13B | 258M | 868M | 251M | 236M | 8.130 |
| Q2 '25 | 1.05B | 116M | 929M | -718M | -514M | -8.250 |
| Q1 '25 | 898M | 105M | 793M | -93M | 139M | -1.520 |
| Q4 '24 | 1.09B | 129M | 959M | 191M | 397M | 6.600 |
| Q3 '24 | 1.05B | 112M | 943M | 215M | 425M | 6.610 |
Insider Transactions View All
| Carr Patricia filed to sell 6,512 shares at $182.9. March 9 '26 |
| COZADD BRUCE C filed to sell 405,796 shares at $187.8. March 4 '26 |
| COZADD BRUCE C filed to sell 406,029 shares at $186.7. March 4 '26 |
| COZADD BRUCE C filed to sell 408,637 shares at $186.1. March 4 '26 |
| RIEDEL NORBERT G filed to sell 7,024 shares at $192. March 2 '26 |
Similar companies
Read more about Jazz Pharmaceuticals (JAZZ) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Jazz Pharmaceuticals
The Market Cap of Jazz Pharmaceuticals is $11.4B.
As of today, Jazz Pharmaceuticals' PE (Price to Earnings) ratio is 15.38.
Currently, the price of one share of Jazz Pharmaceuticals stock is $180.32.
The JAZZ stock price chart above provides a comprehensive visual representation of Jazz Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Jazz Pharmaceuticals shares. Our platform offers an up-to-date JAZZ stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Jazz Pharmaceuticals (JAZZ) does not offer dividends to its shareholders. Investors interested in Jazz Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Jazz Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
